Goldman Sachs Starts AMGN & BIIB at 'Sell', CELG & GILD at 'Neutral', and ALXN at Conviction Buy
Tweet Send to a Friend
Goldman Sachs initiates coverage on big biotech with a 'Cautious' view. "Unlike the Street, we expect continued downward revisions ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
